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Abstract
To date, most genetic association analyses of smoking behaviors have been conducted in
populations of European ancestry and many of these studies focused on the phenotype that
measures smoking quantity, i.e. cigarettes per day. Additional association studies in diverse
populations with different linkage disequilibrium (LD) patterns and an alternate phenotype, such
as total tobacco exposure which accounts for intermittent periods of smoking cessation within a
larger smoking period as measured in large cardiovascular risk studies, can aid the search for
variants relevant to smoking behavior. For these reasons, we undertook an association analysis
using a genotyping array that includes 2100 genes to analyze smoking persistence in unrelated
African-American participants from The Atherosclerosis Risk in Communities (ARIC) study. A
locus located ~ 4 Kb downstream from the 3’ UTR of the Brain-Derived Neurotrophic Factor
(BDNF) significantly influenced smoking persistence. In addition, independent variants
rs12915366 and rs12914385 in the cluster of genes encoding nicotinic acetylcholine receptor
subunits (CHRNA5-CHRNA3-CHRNB4) on 15q25.1 were also associated with the phenotype in
this sample of African American subjects. To our knowledge, this is the first study to more
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extensively evaluate the genome in the African American population as a limited number of
previous studies of smoking behavior in this population included evaluations of only single
genomic regions.
INTRODUCTION
Cigarette smoking continues to be the leading cause of preventable death in the United
States due to its causative link to cancer, cardiovascular, and respiratory disease. The burden
of lung cancer is greater in African-Americans compared to Caucasians (1) with the average
1975–2007 annual age-adjusted per 100,00 incidence and mortality rates of lung cancer in
African Americans of 81.8 and 63.4 respectively, in comparison to 64.1 and 53.9 for
Caucasians (2). Despite the increased risk, published studies evaluating genetic risk of
tobacco dependence in African Americans with common SNPs are limited to evaluations of
individual genomic regions.
To this end, we evaluated smoking persistence in African American participants from the
ARIC study to advance our understanding of tobacco addiction genetics using an innovative
phenotype in genetic association analyses of smoking measured in pack years that
incorporates information on total nicotine exposure accounting for periods of time of
intermittent smoking cessation within a longer period of smoking.
MATERIALS AND METHODS
Study Participants
Participants were a part of The National Heart, Lung, and Blood Institute’s ARIC study. Our
total sample consisted of 1,710 African American current or former smokers (44.1% of the
total sample) who were 45–65 years of age. The mean age of smoking initiation for the
participants was 19.5 and 50.2% of the total sample were male. Intermittency in smoking
(greater than one year) was reported by 28% of the subjects.
Phenotype
Since tobacco use influences both the risk and progression of heart disease, information
regarding individual smoking patterns is extensive in the ARIC study. The phenotype we
investigated here is smoking persistence, as measured by pack years of cigarette exposure.
Because individual tobacco use varies over time, single time point measures like current
cigarettes smoked per day may provide a less accurate estimate of overall smoking behavior.
For this reason, we evaluated smoking persistence using a method that accounts for the
period(s) of abstaining from smoking within a longer overall period of smoking. The pack-
year variable was calculated according to the following formulae:
Current Smokers: PCKYR= AVGCIGDY/20 × ((CURAGE-AGEINIT)-NONSMK)
Former Smokers: PCKYR= AVGCIGDY/20 × ((AGEQUIT-AGEINIT)-NONSMK)
(Abbreviations: PCKYR=Pack-Year; AVGCIGDY=Lifetime Average Cigarettes per Day;
CURAGE=Current age; AGEINIT=Age of smoking initiation; AGEQUIT=Age Quit
Smoking; NONSMOK= Intermittent non-smoking period (i.e. total period of non-smoking
in the overall smoking period))
Genotyping Assay
Samples from the ARIC study were genotyped as part of the Candidate Gene Association
Resource (CARe) project (3). The content of the genotyping array, ITMAT-Broad-CARe or
“IBC chip”, is informed by GWAS, expression quantitative trait loci, pathway-based
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approaches and comprehensive literature searching. It includes loci relevant to addiction. As
an example, it contains densely spaced SNPs from 84 of the 130 genes from the “addiction
array” (4) and additional genes that are not on the addiction array, but were found to be
associated with addiction phenotypes in later genetic association studies.
The loci on the IBC chip are divided into three groups: Group 1 (n = 435 loci) - genes and
regions with a high likelihood of functional significance (Tag SNPs selected to capture
known variation with minor allele frequency (MAF) > 0.02 and an r2 of at least 0.8 in
HapMap populations); Group 2: (n=1,349 loci) - candidate loci that are potentially involved
in phenotypes of interest or established loci that required very large numbers of tagging
SNPs (Tag SNPs selected to capture known variation with MAF > 0.05 with an r2 of at least
0.5 in HapMap populations); Group 3: (n=232 loci) - comprised mainly of the larger genes
(100 kb) which were of lower interest a priori to the investigators (includes only
nonsynonomous SNPs and known functional variants). The average number of SNPs across
the Group 1 and Group 2 loci of IBC was compared with GWAS products. The average
coverage for Group 1 loci is ~36.5 SNPs per locus on the IBC chip. The Illumina Human1M
and Affymetrix 6.0 platform, for comparison, have an average of ~28.0 and ~17.4 SNPs
respectively across the equivalent IBC loci. The average number of SNPs observed for the
Group 2 loci is ~16.3 SNPs, which is comparable with the current GWAS products.
(Additional details regarding the design of the IBC chip have been described in Keating et
al. 2008 (5). In toto, 49,320 SNPs were chosen to map ~2,100 candidate gene loci. For
detailed genotyping and QC information, see Musunuru et al. (3).
Statistical Analyses
The pack-year phenotype was Box-Cox transformed (Lambda = 0.2). Phenotype residuals
were constructed with adjustment for age and gender. The standardized residual served as
the phenotype in genotype-phenotype association analysis. Generation of residuals was
performed with the R statistical package (The R Foundation for Statistical Computing,
Vienna, Austria). Association analysis was performed in PLINK (6) using linear regression
under an additive genetic model. To address concerns about population stratification, we
conducted principle component analysis as implemented in EIGENSTRAT (7). The first ten
principal components were included as covariates in the genetic association analysis. All
results were adjusted for residual inflation using the genomic control method. Bonferonni
adjustment for multiple comparison was set at an alpha level of 0.05/50,000 = 1×10−6.
The imputation, resulting in 270,000 total SNPs, was done using a combined CEU+YRI
reference panel including SNPs segregating in both CEU and YRI, as well as SNPs
segregating in one panel and monomorphic and nonmissing in the other. For imputation of
IBC individuals, the use of the CEU+YRI panel resulted in an allelic concordance rate of
~95.6%, calculated as 1 – 1/2* |imputed_dosage – chip_dosage|. This rate is comparable to
rates calculated for individuals of African descent imputed with the HapMap 2 YRI
individuals (8). In the first step of imputation, individuals with pedigree relatedness or
cryptic relatedness (pi_hat > 0.05) were filtered. Recombination and error rate estimates for
the entire sample were calculated based on a subset of random individuals. Next, these rates
were used to impute all sample individuals across the entire reference panel. Results were
filtered for imputation at an RSQ_HAT less than 0.6 and a MAF threshold of 0.01.
RESULTS
Our analysis did not result in a significant inflation of the χ2-test statistic (genomic control
inflation factor (λGC) = 1.00165). Single nucleotide polymorphisms that were the most
strongly associated with smoking persistence in the ARIC study are summarized in Table 1.
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Variants rs10767658 and rs925946, exhibited the strongest association where each
additional copy of rs10767658*C minor allele and rs925946*T minor allele corresponded to
an increase in smoking persistence of ~3.95 (SE = 0.75; p=1.6×10−7) pack/years (see Figure
1 showing a regional plot of 11p14.1). Linkage disequilibrium between these two variants is
high (r2=0.997) and the conditional analysis result shows a single signal in the region (see
Supplementary Figure 1 conditioning on the most significant SNP in our study).
We also observed associations between smoking persistence and two distinct loci on
chromosome 15 near and in the CHRNA5-CHRNA3-CHRNB4 cluster, although these
associations did not pass the correction for multiple comparisons (set at 1×10−6). The
associated SNPs, representing the two distinct loci, rs12915366 in PSMA4 (proteasome
subunit alpha type-4) and rs12914385 in CHRNA3 (nicotinic receptor alpha 3 subunit) have
low LD between them (r2=0.028) (See Figure 2). The minor A allele of rs12915366 was
associated with a reduction of 3.47 (SE=1.63; p=3.58×10−05) pack-years per allele, while
the major C allele of rs12914385 in CHRNA3 was associated with a decrease of 3.25
(SE=0.82; p=7.62×10−5) pack years per allele.
The total number of SNPs analyzed from the chromosome 11 region (27.6–27.75 million
bases pairs (Mbp)) was 79 (12 genotyped plus 67 imputed). The total number of SNPs
analyzed from the chromosome 15 region (76.5–76.75 Mbp) was 147 (12 genotyped plus
135 imputed). Please see Figures 1 and 2 for further information.
DISCUSSION
We were able to advance our understanding of tobacco addiction genetics by using a richly-
phenotyped sample from the population of African ancestry known to have a reduced LD
compared to European ancestry genomes (9) in whom most smoking behavior genetics
studies have been conducted. We found that variants located downstream of the 3’ BDNF
UTR were the most strongly associated with smoking persistence. Interestingly, the
statistically significant variant rs925946 in our study has been associated with adult (10) and
more recently childhood obesity (11) risk. This finding suggests that studies evaluating
natural and drug reward may be modeled by this locus.
Recently it has been found that transcription of the BDNF gene (up to 11 exons and ~70kB
long) (12,13) can be initiated from nine distinct functional promoters in humans. Regardless
of which promoter is used, all BDNF transcripts are processed at two alternative
polyadenylation sites, producing two sets of mRNA that carry either the long or the short 3’
UTR, and both of these encode the same BDNF protein arising from the single, last “3’
exon” (12,14). Variants found in our study are located immediately proximal of the BDNF
3’ UTR region, shown to be central in BDNF transcription.
Our finding maps a locus on Chromosome 11p14.1 for smoking persistence and for the first
time shows the significance of BDNF when the genome is evaluated beyond a single locus
analysis as well as demonstrates an association in the African American population.
Investigators in an earlier single candidate gene analysis (15) found that a haplotype block
within BDNF (Chr11:27,650,817–27,688,559) was associated with smoking behavior in
European Americans, but a haplotype block in a similar region (Chr11:27,659,764–
27,688,559) in African Americans was not (individual SNPs were not associated with
smoking behavior in either population). The most significant SNP in our study, rs10767658,
is located at Chr11: 27, 628,828, therefore future analyses of BDNF should extend to the
region downstream of the BDNF 3’ exon. While Beuten et al (24) analyzed a single
candidate gene and smoking behavior, the question of BDNF’s significance against a more
extensive coverage of the genome remained open. Our analysis shows that the effect of
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BDNF on smoking persistence is significant when the genome is evaluated more
extensively.
In addition to BDNF’s influence on smoking persistence, in an analysis of an additional
smoking behavior phenotype comparing individuals who never smoked versus those who
ever smoked, a non-synonomous variant rs6265, genotyped in our study and in low LD
(r2=0.012) with our top variant, has been recently shown to significantly mediate smoking
initiation (16) (additional information regarding the analysis of this variant in our dataset can
be found in Supplementary Figure 1).
Since its discovery three decades ago, the role of BDNF in the differentiation and survival of
neurons in the central nervous system has been firmly established. More recently it has been
shown that the neurotrophin is critical for changes in synaptic strength that are important for
information storage during memory formation (17). This may be relevant in tobacco
addiction as relapse episodes occur following exposure to smoking cues because previously
neutral stimuli acquire incentive motivational value when repeatedly paired with nicotine
(18,19). Because BDNF is known to elicit a plethora of functions in the brain via activation
of the tropomyosin-related receptor tyrosine kinase B (TrkB), mechanisms additional to the
mnemonic processes important for smoking persistence may include the trophic effects of
BDNF on the dopaminergic neurons that are at the center of the reward circuits activated by
nicotine (20) as well as nicotine-induced BDNF expression changes (21).
Because our study was conducted in a cohort of African Americans, a population with lower
levels of LD in comparison to populations of European descent in whom most studies of
smoking behavior have been conducted, we were able to map the location of variants that
are associated with smoking persistence in the CHRNA3/CHRNA5/CHRNB4 gene cluster on
15q25.1. We have identified two independent loci in this region. The top SNP, rs12915366,
is located in PSMA4 and, as has been shown previously in European ancestry and African
American populations, SNPs in this region, 5’ of CHRNA5, associated with smoking
(22,16,23) and lung cancer (24,25,26), are thought to be tagging a distal enhancer region
(~13 kilobases from CHRNA5), which regulates the expression of CHRNA5 (27). Our
second locus, rs12914385 - a SNP in low LD (r2=0.028) with the top SNP rs12915366 in
this region – is located in CHRNA3 and has been associated with lung cancer in a two-stage
genome-wide case:control study of self-reported European Ancestry participants (28, 29). A
literature search of previously-associated SNPs with either nicotine dependence or lung
cancer near rs12914385 for African Americans showed that a CHRNA5 SNP rs16969968
was previously associated with nicotine dependence (23). This SNP is in low LD (r2 = 0.25)
with rs12914385 - our top SNP in this region - and, as in the previous study (23), in our
analysis rs16969968 showed a weak association with smoking persistence (p=0.012),
possibly due to a low MAF of 0.07 in the African American population. Two CHRNA3
variants, rs578776 (30) and rs1051730 (25, 26) in the same CHRNA3 intron as rs12914385
have been associated with lung cancer risk in African Americans and are in moderate
(r2=0.58) and low (r2=0.006) LD with rs12914385, respectively. Further fine mapping
efforts should aid the search of functional variant(s) in this locus.
In conclusion, results of our work support the idea of using alternate phenotypes and
populations to efficiently map regions in the genome that influence smoking behavior. We
have shown that a locus immediately downstream of BNDF 3’ UTR is a mediator of
smoking behavior and our results on chromosome 15q25.1 show that distinct variants
modulate smoking persistence in African Americans. We have more extensively evaluated
the genome (~2,100 genes) in the African American population and extended the work of
previous studies which evaluated a limited number of genomic loci in relation to smoking
behavior in this United States population.
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Association between chromosome 11p14.1 variants and smoking persistence. Several
common variants, including rs10767658 (purple triangle) and rs925946 (red triangle),
cluster on 11p14.1 and show associations with smoking persistence in African Americans.
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Association between chromosome 15q25.1 variants and smoking persistence. Note low LD
between rs12915366 (with the lowest p value in PSMA4) and rs12914385 (with the lowest p
value in CHRNA3).
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